SutroVax’s Alan Kimura Joins Enzyvant as Chief Medical Officer

Alan Kimura has been appointed chief medical officer of Cambridge, MA-based Enzyvant. Before joining Enzyvant, Kimura was chief medical officer of Foster City, CA-based SutroVax. His experience also includes posts at Shire (NASDAQ:[[ticker:SHPG]]), Novartis Vaccines, and Translate Bio (NASDAQ: [[ticker:TBIO]]). Enzyvant is the rare disease subsidiary of Switzerland-based Roivant Sciences. The company is preparing to file for FDA approval of RVT-802, a regenerative medicine therapy to treat complete DiGeorge anomaly, a rare disease in which babies are born without an organ called the thymus.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.